
Revvity Inc (RVTY) Stock Forecast & Price Target
Revvity Inc (RVTY) Analyst Ratings
Bulls say
Revvity's stock outlook is positively influenced by its strategic transition from traditional testing (TST) to Interferon Gamma Release Assays (IGRA), anticipated to drive annual market growth by several basis points. The company boasts a diversified product portfolio, highlighted by a high-growth software segment—Signals—which accounts for approximately 10% of sales, alongside a robust immunodiagnostics franchise contributing around 30% of sales. Furthermore, Revvity has demonstrated enhanced profitability potential through operating leverage, expanding market share in key areas such as autoimmune testing and reagents, which positions the company favorably for sustained long-term financial success.
Bears say
Revvity's performance in the Chinese market has been severely impacted, particularly in the immunodiagnostics segment, which saw a significant decline in revenue, recording a downward percentage decrease in 2Q25, further contributing to a projected reduction in overall revenue contribution from China to approximately 7% by 2025. Additionally, the company faces potential headwinds from unfavorable economic conditions and cuts in industry funding, which may lead to decreased customer demand for its products and adversely affect growth and market share. Furthermore, macroeconomic challenges such as product shortages, inflation, transit delays, and labor shortages pose risks to Revvity's supply chain and operational efficacy, further complicating the company's financial outlook.
This aggregate rating is based on analysts' research of Revvity Inc and is not a guaranteed prediction by Public.com or investment advice.
Revvity Inc (RVTY) Analyst Forecast & Price Prediction
Start investing in Revvity Inc (RVTY)
Order type
Buy in
Order amount
Est. shares
0 shares